News
AMGN
295.93
-1.83%
-5.51
Wolfe Research starts Amgen at Peer Perform given approaching patent cliffs
TipRanks · 9h ago
Amgen’s Uplizna shows potential efficacy in rare inflammatory diseases
TipRanks · 11h ago
AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024
Reuters · 11h ago
Dow's 238-point fall led by losses in UnitedHealth, Salesforce shares
MarketWatch · 12h ago
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate
NASDAQ · 12h ago
Gilead, Vertex initiated as new big biotech buys at Citi
Seeking Alpha · 13h ago
5 Healthcare Stocks to Buy in a Beaten-Up Sector
Barron‘s · 14h ago
Amgen call volume above normal and directionally bullish
TipRanks · 14h ago
Dow's 111-point drop led by losses for Salesforce, Cisco stocks
MarketWatch · 15h ago
Dow Movers: CSCO, DIS
NASDAQ · 17h ago
2 Dividend Stocks to Buy Hand Over Fist in November
NASDAQ · 17h ago
Ex-Dividend Reminder: Amgen, eXp World Holdings and Jefferies Group
NASDAQ · 17h ago
American upgraded, Regeneron initiated: Wall Street’s top analyst calls
TipRanks · 18h ago
BUZZ-Citi starts coverage on Amgen with 'neutral' on caution over obesity drug
Reuters · 18h ago
What Analysts Are Saying About Amgen Stock
Benzinga · 18h ago
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Shattuck Labs (STTK) and Astria Therapeutics (ATXS)
TipRanks · 19h ago
Evercore ISI Remains a Buy on Amgen (AMGN)
TipRanks · 19h ago
Amgen Initiated at Neutral by Citigroup
Dow Jones · 19h ago
Amgen Price Target Announced at $335.00/Share by Citigroup
Dow Jones · 19h ago
Citigroup Initiates Coverage On Amgen with Neutral Rating, Announces Price Target of $335
Benzinga · 20h ago
More
Webull provides a variety of real-time AMGN stock news. You can receive the latest news about Amgen Inc through multiple platforms. This information may help you make smarter investment decisions.
About AMGN
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.